Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8270)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 28, 2015 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-1631 [PMID: 26140082 DOI: 10.4254/wjh.v7.i12.1617] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i12/1617.htm |
| Number | Citing Articles |
| 1 |
Saima Mushtaq, Atika Mansoor, Muhammad Umar, Amjad Khan, Saima Siddiqi, Sobia Manzoor. Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan. Journal of Medical Virology 2020; 92(12): 3475 doi: 10.1002/jmv.25745
|
| 2 |
Sanem Karadağ Gencer, Yasemin Üstündağ, Kağan Huysal. The Effect of HCV-RNA, HCV-Genotype 1b, and Anti-HCV Positivity on Laboratory Parameters. Viral Hepatitis Journal 2023; 29(2): 52 doi: 10.4274/vhd.galenos.2023.2022-11-2
|
| 3 |
Maissa El-Raziky, Marwa Khairy, Ahmed Fouad, Ahmed Salama, Aisha Elsharkawy, Omnia Tantawy. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. Journal of Interferon & Cytokine Research 2018; 38(3): 129 doi: 10.1089/jir.2017.0137
|
| 4 |
In Soo Oh, Joung Won Won, Hyung Joon Kim, Hyun Woong Lee. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. The Korean Journal of Internal Medicine 2017; 32(6): 1010 doi: 10.3904/kjim.2016.405
|
| 5 |
Vijay Gayam, Muhammad Rajib Hossain, Mazin Khalid, Sandipan Chakaraborty, Osama Mukhtar, Sumit Dahal, Amrendra Kumar Mandal, Arshpal Gill, Pavani Garlapati, Sreedevi Ramakrishnaiah, Khalid Mowyad, Jagannath Sherigar, Mohammed Mansour, Smruti Mohanty. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. Gut and Liver 2018; 12(6): 694 doi: 10.5009/gnl18004
|
| 6 |
N. K. T. Hlaing, R. A. Mitrani, S. T. Aung, W. W. Phyo, M. Serper, A. M. M. Kyaw, A. H. Bwa, K. M. Win, K. R. Reddy. Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience. Journal of Viral Hepatitis 2017; 24(11): 927 doi: 10.1111/jvh.12721
|
| 7 |
Hend Ibrahim Shousha, Yasmin Saad, Doa’a A. Saleh, Hosam Dabes, Magdy Alserafy, Yehia ElShazly, Mohamed Said. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. European Journal of Gastroenterology & Hepatology 2020; 32(8): 1017 doi: 10.1097/MEG.0000000000001612
|
| 8 |
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany, Sherief Abd-Elsalam. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology 2020; 2020: 1 doi: 10.1155/2020/9075905
|
| 9 |
Moisés Uriarte-Pinto, Herminia Navarro-Aznarez, Natalia De La Llama-Celis, Piedad Arazo-Garcés, Ana María Martínez-Sapiña, María Reyes Abad-Sazatornil. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. International Journal of Clinical Pharmacy 2018; 40(3): 608 doi: 10.1007/s11096-018-0621-0
|
| 10 |
N. Bhardwaj, M. Ragonnet‐Cronin, B. Murrell, K. Chodavarapu, R. Martin, S. Chang, M. D. Miller, J. J. Feld, M. Sulkowski, A. Mangia, J. O. Wertheim, A. Osinusi, J. McNally, D. Brainard, H. Mo, E. S. Svarovskaia. Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens. Journal of Viral Hepatitis 2018; 25(4): 344 doi: 10.1111/jvh.12825
|
| 11 |
Crina Fofiu, Alina Boeriu, Felicia Coman, Alexandru Fofiu, Nikola Panic, Milutin Bulajic, Daniela Dobru. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology 2019; 18(1): 137 doi: 10.5604/01.3001.0012.7905
|
| 12 |
Stephanie Popping, Valeria Cento, Federico García, Francesca Ceccherini-Silberstein, Carole Seguin-Devaux, David A.M.C. Vijver, Charles A. Boucher. The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication 2018; 4(3): 179 doi: 10.1016/S2055-6640(20)30267-3
|
| 13 |
Ayman Yosry, Rabab Fouad, Shereen A. Alem, Aisha Elsharkawy, Mohammad El-Sayed, Noha Asem, Ehsan Hassan, Ahmed Ismail, Gamal Esmat. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology 2016; 17(2): 78 doi: 10.1016/j.ajg.2016.05.002
|
| 14 |
Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 2022; 121(11): 2265 doi: 10.1016/j.jfma.2022.04.020
|
| 15 |
Michael Bright Yakass, David Franco, Osbourne Quaye. Suppressors of Cytokine Signaling and Protein Inhibitors of Activated Signal Transducer and Activator of Transcriptions As Therapeutic Targets in Flavivirus Infections. Journal of Interferon & Cytokine Research 2020; 40(1): 1 doi: 10.1089/jir.2019.0097
|
| 16 |
Stefan Zeuzem, Graham R. Foster, Stanley Wang, Armen Asatryan, Edward Gane, Jordan J. Feld, Tarik Asselah, Marc Bourlière, Peter J. Ruane, Heiner Wedemeyer, Stanislas Pol, Robert Flisiak, Fred Poordad, Wan-Long Chuang, Catherine A. Stedman, Steven Flamm, Paul Kwo, Gregory J. Dore, Gladys Sepulveda-Arzola, Stuart K. Roberts, Ruth Soto-Malave, Kelly Kaita, Massimo Puoti, John Vierling, Edward Tam, Hugo E. Vargas, Rafi Bruck, Francisco Fuster, Seung-Woon Paik, Franco Felizarta, Jens Kort, Bo Fu, Ran Liu, Teresa I. Ng, Tami Pilot-Matias, Chih-Wei Lin, Roger Trinh, Federico J. Mensa. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine 2018; 378(4): 354 doi: 10.1056/NEJMoa1702417
|
| 17 |
Lindsy Liu, Monika N. Daftary, Mohammad S. Alzahrani, Chiemena Ohanele, Mary K. Maneno. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.. Journal of the National Medical Association 2021; 113(2): 147 doi: 10.1016/j.jnma.2020.08.006
|
| 18 |
L Milazzo, A Lai, E Calvi, P Ronzi, V Micheli, F Binda, AL Ridolfo, C Gervasoni, M Galli, S Antinori, S Sollima. Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy. HIV Medicine 2017; 18(4): 284 doi: 10.1111/hiv.12429
|
| 19 |
Wendy Carter, Sarah Connelly, Kimberly Struble. Reinventing HCV Treatment: Past and Future Perspectives. The Journal of Clinical Pharmacology 2017; 57(3): 287 doi: 10.1002/jcph.830
|
| 20 |
Christophe Hézode, Slim Fourati, Stéphane Chevaliez, Giovanna Scoazec, Alexandre Soulier, Anne Varaut, Murielle François, Isaac Ruiz, Françoise Roudot-Thoraval, Ariane Mallat, Jean-Michel Pawlotsky. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C. Clinical Infectious Diseases 2017; 64(11): 1615 doi: 10.1093/cid/cix214
|
| 21 |
Mehmet Cabalak, Tayibe Bal, Yusuf Onlen, Mehmet Demir. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. Tropical Doctor 2020; 50(2): 141 doi: 10.1177/0049475519892082
|
| 22 |
Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, Zayani Sims, Mary McLaughlin, Angie Price, Rachel Silk, Chloe Gross, Elizabeth Akoth, Maryellen McManus, Benjamin Emmanuel, Shikha Shrivastava, Lydia Tang, Amy Nelson, Gebeyehu Teferi, Jose Chavez, Brian Lam, Hongmei Mo, Anuoluwapo Osinusi, Michael A. Polis, Henry Masur, Anita Kohli, Shyamasundaran Kottilil. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clinical Infectious Diseases 2015; : civ897 doi: 10.1093/cid/civ897
|
| 23 |
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D’Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infectious Diseases 2018; 18(1) doi: 10.1186/s12879-018-3125-6
|
| 24 |
Snezana Jovanovic-Cupic, Ana Bozovic, Milena Krajnovic, Nina Petrovic. Hepatitis C - From Infection to Cure. 2018; doi: 10.5772/intechopen.76417
|
| 25 |
Onyema Ogbuagu, Ritche Hao, Michael Virata, Merceditas S. Villanueva, Maricar Malinis. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017; 6: 620 doi: 10.12688/f1000research.11397.1
|
| 26 |
Jasmine Schulkind, Brian Stephens, Farsana Ahmad, Linda Johnston, Sharon Hutchinson, Donna Thain, Zoe Ward, Peter Vickerman, Matt Hickman, John F. Dillon. High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. Journal of Viral Hepatitis 2019; 26(5): 519 doi: 10.1111/jvh.13035
|
| 27 |
Andréa Marques Vieira da Silva, Lucia Elena Alvarado-Arnez, Tamiris Azamor, Leonardo Ribeiro Batista-Silva, Thyago Leal-Calvo, Ohanna Cavalcanti de Lima Bezerra, Marcelo Ribeiro-Alves, Fernanda de Souza Gomes Kehdy, Patrícia Cristina da Costa Neves, Camilla Bayma, Jane da Silva, Alessandro Fonseca de Souza, Marcelo Muller, Elisabete Ferreira de Andrade, Ana Carolina Magalhães Andrade, Eliane Matos dos Santos, Janaína Reis Xavier, Maria De Lourdes De Sousa Maia, Rolando Páez Meireles, Hugo Nodarse Cuni, Guilherme Becker Sander, Paulo Dornelles Picon, Denise C S Matos, Milton Ozório Moraes. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Frontiers in Cellular and Infection Microbiology 2021; 11 doi: 10.3389/fcimb.2021.656393
|
| 28 |
Radwa R. El-Tahan, Ahmed M. Ghoneim, Hosam Zaghloul. 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. Journal of Advanced Research 2018; 10: 39 doi: 10.1016/j.jare.2018.01.004
|
| 29 |
Mouna Rajhi, Kais Ghedira, Anissa Chouikha, Ahlem Djebbi, Imed Cheikh, Ahlem Ben Yahia, Amel Sadraoui, Walid Hammami, Msaddek Azouz, Nabil Ben Mami, Henda Triki, Jason Blackard. Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa. PLOS ONE 2016; 11(4): e0153761 doi: 10.1371/journal.pone.0153761
|
| 30 |
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele', Tommaso Trenti. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. Journal of Clinical and Experimental Hepatology 2019; 9(4): 522 doi: 10.1016/j.jceh.2018.07.004
|
| 31 |
Christophe Hézode, Piero L. Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Moises Diago, Yves Horsmans, Lawrence Serfaty, Ferenc Szalay, Giovanni B. Gaeta, Ramon Planas, Michael Schlag, Isabelle Lonjon‐Domanec, Edmund Omoruyi, Ralph DeMasi, Stefan Zeuzem. Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver International 2017; 37(9): 1304 doi: 10.1111/liv.13376
|
| 32 |
Kattareeya Kumthip, Niwat Maneekarn. The role of HCV proteins on treatment outcomes. Virology Journal 2015; 12(1) doi: 10.1186/s12985-015-0450-x
|
| 33 |
Naveen Tmu, Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. Journal of Clinical and Experimental Hepatology 2019; 9(1): 4 doi: 10.1016/j.jceh.2018.02.009
|
| 34 |
Karina González-Aldaco, Luis A. Torres-Reyes, Claudia Ojeda-Granados, Alexis José-Ábrego, Nora A. Fierro, Sonia Román. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy. Annals of Hepatology 2018; 17(6): 908 doi: 10.5604/01.3001.0012.7191
|
| 35 |
Tatyana Kushner, Douglas Dieterich, Behnam Saberi. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Current Opinion in Gastroenterology 2018; 34(3): 132 doi: 10.1097/MOG.0000000000000431
|
| 36 |
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.550205
|
| 37 |
Braira Wahid, Shazia Rafique, Komal Saleem, Amjad Ali, Muhammad Idrees. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018; 38(3): 122 doi: 10.1089/jir.2017.0129
|
| 38 |
Malik Sallam, Rawan Batarseh, Anas Natsheh, Jumana Abbadi, Esraa Al-Fraihat, Alaa’ Yaseen, Doaa Kaddomi, Nadia Khamees, Azmi Mahafzah, Gülşen Özkaya Şahin. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infectious Diseases 2020; 20(1) doi: 10.1186/s12879-019-4735-3
|
| 39 |
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk. Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C. Terapevticheskii arkhiv 2019; 91(8): 67 doi: 10.26442/00403660.2019.08.000384
|
| 40 |
Paula Eckardt, Jianli Niu, Angela Savage, Tara Griffin, Elizabeth Sherman. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital. Journal of the International Association of Providers of AIDS Care (JIAPAC) 2019; 18: 232595821983559 doi: 10.1177/2325958219835590
|
| 41 |
D. A. Lioznov, N. V. Dunaeva, N. H. Chung, O. V. Gorchakova, T. V. Antonova. Chronic hepatitis C: modern condition of the problem. Nephrology (Saint-Petersburg) 2019; 23(4): 36 doi: 10.24884/1561-6274-2019-23-4-36-46
|
| 42 |
Hirohito Yoneyama, Asahiro Morishita, Hisakazu Iwama, Koji Fujita, Takahiro Masaki, Joji Tani, Tomoko Tadokoro, Takako Nomura, Teppei Sakamoto, Kyoko Oura, Kei Takuma, Mai Nakahara, Shima Mimura, Akihiro Deguchi, Makoto Oryu, Kunihiko Tsutsui, Takashi Himoto, Kunitada Shimotohno, Takaji Wakita, Hideki Kobara, Tsutomu Masaki. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct‐acting antiviral therapies. Journal of Gastroenterology and Hepatology 2021; 36(4): 1126 doi: 10.1111/jgh.15224
|
| 43 |
Courtney M. Boucher, Anne Walsh, Christopher P. Forest. Healing livers, saving lives. Journal of the American Academy of Physician Assistants 2016; 29(5): 20 doi: 10.1097/01.JAA.0000482295.08412.4a
|
| 44 |
Zachary DeNardo, Minha Choi, Michelle Stiller, Dillon Buechel. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation. The Kaohsiung Journal of Medical Sciences 2017; 33(11): 584 doi: 10.1016/j.kjms.2017.06.007
|
| 45 |
Iosif Marincu, Felix Bratosin, Manuela Curescu, Oana Suciu, Mirela Turaiche, Bianca Cerbu, Iulia Vidican. Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. Medicina 2021; 57(9): 986 doi: 10.3390/medicina57090986
|
| 46 |
Yu. V. Ostankova, A. V. Semenov, E. B. Zueva, E. N. Serikova, A. N. Schemelev, D. E. Valutite, H. K.T. Huinh, S. A. Egorova, A. A. Totolian. Prevalence of hepatitis B and C viral markers among apparently healthy residents of the Socialist Republic of Vietnam (Southern Vietnam). Russian Journal of Infection and Immunity 2021; 11(6): 1131 doi: 10.15789/2220-7619-TPO-1793
|
| 47 |
Supradip Dutta, Aritra Biswas, Sagnik Bakshi, Promisree Choudhury, Raina Das, Shreyasi Nath, Prosanto Chowdhury, Maitreyee Bhattacharyya, Sharmistha Chakraborty, Shanta Dutta, Provash Chandra Sadhukhan. Molecular Epidemiology of HCV Infection among Multi-Transfused β-Thalassemia Patients in Eastern India: A Six-Year Observation. Thalassemia Reports 2023; 13(3): 165 doi: 10.3390/thalassrep13030016
|
| 48 |
Emma Gray, David J. Pasta, Suzanne Norris, Aisling O’Leary. Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC Health Services Research 2017; 17(1) doi: 10.1186/s12913-017-2188-1
|
| 49 |
Onyema Ogbuagu, Ritche Hao, Michael Virata, Merceditas S. Villanueva, Maricar Malinis. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2018; 6: 620 doi: 10.12688/f1000research.11397.2
|
| 50 |
Ramsha Khalid, Muhammad Faraz Anwar, Muhammad Aanish Raees, Sadaf Naeem, Syed Hani Abidi, Syed Ali. An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug–protein interaction. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-77720-9
|
| 51 |
Lone Wulff Madsen, Peer Brehm Christensen, Anne Øvrehus, Dorthe Marie Sjødahl Bryde, Dorte Kinggaard Holm, Søren Thue Lillevang, Christian Nielsen. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.885824
|
| 52 |
Niels C Pedersen, Yunjeong Kim, Hongwei Liu, Anushka C Galasiti Kankanamalage, Chrissy Eckstrand, William C Groutas, Michael Bannasch, Juliana M Meadows, Kyeong-Ok Chang. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of Feline Medicine and Surgery 2018; 20(4): 378 doi: 10.1177/1098612X17729626
|
| 53 |
Lubomír Skladaný, Marian Oltman, Soňa Fraňková, Sylvia Dražilová, Petr Husa, Jan Šperl, Václav Hejda, Petr Urbánek, Svetlana Adamcová-Selčanová, Martin Janičko, Pavol Kristian, Viera Kupčová, Marek Rác, Ivan Schréter, Ladislav Virág, Adriana Liptáková, Miriam Ondrášová, Peter Jarčuška. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. International Journal of Public Health 2020; 65(9): 1723 doi: 10.1007/s00038-020-01496-y
|
| 54 |
J. D. Leask, J. F. Dillon. Review article: treatment as prevention – targeting people who inject drugs as a pathway towards hepatitis C eradication. Alimentary Pharmacology & Therapeutics 2016; 44(2): 145 doi: 10.1111/apt.13673
|
| 55 |
Isabella Esposito, Sebastián Marciano, Leila Haddad, Omar Galdame, Alejandra Franco, Adrián Gadano, Diego Flichman, Julieta Trinks. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. Viruses 2018; 11(1): 3 doi: 10.3390/v11010003
|
| 56 |
Elisabete Andrade, Daniele Rocha, Marcela Fontana-Maurell, Elaine Costa, Marisa Ribeiro, Daniela Tupy de Godoy, Antonio G.P. Ferreira, Amilcar Tanuri, Patrícia Alvarez, Rodrigo Brindeiro. One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil. The Brazilian Journal of Infectious Diseases 2018; 22(5): 418 doi: 10.1016/j.bjid.2018.08.003
|
| 57 |
Samira Basharkhah, Faezeh Sabet, Sanaz Ahmadi Ghezeldasht, Arman Mosavat, Hamid Reza Jahantigh, Elham Barati, Khosrow Shamsian, Masoud Saleh‐Moghaddam, Hiva Sharebyani, Tahereh Hassannia, Seyed Ali Akbar Shamsian. Prediction of HCV load using genotype, liver biomarkers, and clinical symptoms by a mathematical model in patients with HCV infection. Microbiology and Immunology 2019; 63(11): 449 doi: 10.1111/1348-0421.12735
|
| 58 |
Fatemeh Sakhaee, Morteza Ghazanfari, Farzam Vaziri, Fatemeh Rahimi Jamnani, Mehdi Davari, Safoora Gharibzadeh, Roohollah Fateh, Farid Abdolrahimi, Shahin Pourazar Dizaji, Abolfazl Fateh, Seyed Davar Siadat. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infection, Genetics and Evolution 2017; 54: 330 doi: 10.1016/j.meegid.2017.07.023
|
| 59 |
Resha Dermawansyah Rusman, Nu’man AS Daud, Muhammad Luthfi Parewangi, Syakib Bakri, Andi Makbul Aman, Haerani Rasyid, Arifin Seweng, Akiko Syawalidhany Tahir. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00217-9
|
| 60 |
Leon Tribolet, Emily Kerr, Christopher Cowled, Andrew G. D. Bean, Cameron R. Stewart, Megan Dearnley, Ryan J. Farr. MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing. Frontiers in Microbiology 2020; 11 doi: 10.3389/fmicb.2020.01197
|